Article Details
Retrieved on: 2022-09-16 22:35:07
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Prospects for AstraZeneca's oral Factor D inhibitor danicopan were looking poor after it failed a phase 2 trial in a rare kidney disease in 2020, ...
Article found on: pharmaphorum.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here